+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Muscle Relaxant Drugs Market - Growth, Trends, and Forecast (2020-2025)

  • ID: 4997486
  • Report
  • March 2020
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Acorda Therapeutics
  • Dr Reddy's laboratories
  • Lannett
  • Neurana Pharmaceuticals
  • Pfizer
  • Teva Pharmaceuticals
  • MORE
Growing geriatric population across the world who are more prone to the musculoskeletal disorder is the major factor driving the growth of market studied. Additionally, increasing prevalence of pain and spasm conditions, increasing focus on the development of novel drugs for the treatment of spasm and pain, frequent product approvals, growing number of surgeries are the other factors that are bolstering the market growth. However, side effects associated with the muscle relaxant drugs is acting as a restraining factor to the market growth.

Key Market Trends

Neuromuscular Blocking Agents segment Holds Significant Share in Muscle Relaxant Drugs Market

Neuromuscular blocking agents are the potent muscle relaxants typically used only during surgery to prevent muscle movement. They are structurally related to acetylcholine, the main neurotransmitter in the body and they cause muscle relaxation by binding to acetylcholine receptors postsynaptically (preventing acetylcholine from binding). This blocks neuromuscular transmission and causes paralysis of the muscle.

These are of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents).

Cisatracurium, Succinylcholine, Doxacurium, Rocuronium etc. are the few examples for Neuromuscular blocking agents. In November 2019, Zydus Cadila has U.S.FDA approval for its generic version of muscle relaxant Cisatracurium Besylate Injection with strengths of 10 mg/5 ml and 200 mg/20 ml given before general anesthesia.

North America dominate the Global Muscle Relaxant Drugs Market

The current growth of the North America Muscle Relaxant Drugs market can be primarily attributed to increasing prevalence of musculoskeletal disorders and on the other side, presence of sophisticated healthcare infrastructure, frequent product approvals, presence of major market players focusing on the development of novel molecules for the treatment of pain and spasm are also acting as the major factors for the growth of the market.

According to Palmer College of Chiropractic commissioned Gallup research study in 2018, Neck and back pain is common among adults in the U.S. About two-thirds of U.S. adults (62%) have had neck or back pain. In March 2017, Zydus Cadila has received approval from the USFDA to market tizanidine hydrochloride capsules, a muscle relaxant, in the American market.

Competitive Landscape

In the market studied, major players are focused on expanding their business in different areas by adopting various market strategies such as partnerships, collaborations, acquisitions and mergers etc. Key developments of the market include - in September 2019, Ipsen Biopharmaceuticals received United States Food and Drug Administration approval ofexpanded use of Dysport (abobotulinumtoxinA) for injection to include the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics
  • Dr Reddy's laboratories
  • Lannett
  • Neurana Pharmaceuticals
  • Pfizer
  • Teva Pharmaceuticals
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Geriatric Population
4.2.2 Increasing Prevalence of Musculoskeletal Disorders
4.3 Market Restraints
4.3.1 Adverse Effects of Muscle Relaxants
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type of Drugs
5.1.1 Facial Muscle Relaxants
5.1.2 Skeletal muscle Relaxants
5.1.3 Neuromuscular Blocking Agents
5.2 By Dristibution Channel
5.2.1 Hospital Pharmacy
5.2.2 Retail Pharmacy
5.2.3 Online Pharmacy
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Acorda Therapeutics
6.1.2 Dr Reddy's laboratories
6.1.3 Ipsen Biopharmaceuticals Inc.
6.1.4 Lannett
6.1.5 Neurana Pharmaceuticals
6.1.6 Pfizer
6.1.7 Teva Pharmaceuticals
6.1.8 Unichem Laboratories
6.1.9 Zydus Cadila

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acorda Therapeutics
  • Dr Reddy's laboratories
  • Ipsen Biopharmaceuticals Inc.
  • Lannett
  • Neurana Pharmaceuticals
  • Pfizer
  • Teva Pharmaceuticals
  • Unichem Laboratories
  • Zydus Cadila
Note: Product cover images may vary from those shown
Adroll
adroll